Evotec AG: Results Of Pre-Clinical Studies Lead To Reduction In Revenues, Nevertheless Profitable And More Than EURO 90 M Cash For 2013 Confirmed

HAMBURG, Germany, Dec. 13, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it is adjusting its guidance regarding Group revenues.

Help employers find you! Check out all the jobs and post your resume.